MDT-AP-3269
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 6.4
- sex
- M
- new_clusters
- C6
- umap1_2d
- 3.144825754
- umap2_2d
- 6.496272639
- umap1_3d
- 2.683624494
- umap2_3d
- -0.921881675
- umap3_3d
- -4.751900738
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.450
- HEME_METABOLISM+0.120
- INTERFERON_ALPHA_RESPONSE+0.080
- MITOTIC_SPINDLE+0.080
- TGF_BETA_SIGNALING+0.060
- PI3K_AKT_MTOR_SIGNALING+0.050
- IL6_JAK_STAT3_SIGNALING+0.010
- INTERFERON_GAMMA_RESPONSE+0.010
- SPERMATOGENESIS+0.010
- COMPLEMENT-0.010
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- MYC_TARGETS_V2-0.440
- ANGIOGENESIS-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- PANCREAS_BETA_CELLS-0.340
- MYOGENESIS-0.330
- CHOLESTEROL_HOMEOSTASIS-0.320
- MYC_TARGETS_V1-0.290
- P53_PATHWAY-0.280
- HYPOXIA-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A3OD-01A-11R-A21T-07 | — | D | 0.829 |
| 2 | TCGA-E2-A15I-01A-21R-A137-07 | — | B | 0.828 |
| 3 | d220785b-6de0-4b89-a402-3d2cdcda4b2f | — | — | 0.825 |
| 4 | SRR4195665 | — | — | 0.817 |
| 5 | TCGA-A7-A26J-01B-02R-A277-07 | — | D | 0.816 |
| 6 | TCGA-44-5645-01A-01R-A278-07 | — | cohortMD2 | 0.816 |
| 7 | MDT-AP-3246 | Med | Medulloblastoma | 0.802 |
| 8 | BS_5PJCHF6V | Med | Medulloblastoma | 0.801 |
| 9 | MDT-AP-0441 | Med | Medulloblastoma | 0.801 |
| 10 | TCGA-A7-A13G-01A-11R-A13Q-07 | — | D | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.080 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.080 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.010 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.010 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |